Please login to the form below

Not currently logged in


This page shows the latest CVnCoV news and features for those working in and with pharma, biotech and healthcare.

CureVac to push ahead with first- and second-generation COVID-19 vaccines

CureVac to push ahead with first- and second-generation COVID-19 vaccines

CVnCoV offered 77% protection against moderate to severe disease and 100% protection against hospitalisation or death in people aged between 18 and 60. ... The candidate features a new, optimised mRNA backbone that causes “earlier and stronger immune

Latest news

More from news
Approximately 7 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts


Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Parkinson’s disease: past, present and future
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...